Robust IPO activity through late 2026, with 249 U.S. listings priced year-to-date as of September 28 raising substantial proceeds amid selective demand for AI, biotech, and consumer names, drives expectations for additional offerings before year-end. Recent September pricings such as ADARx Pharmaceuticals and scheduled debuts including Oura highlight an open window supported by equity market liquidity and investor appetite for growth stories, despite occasional postponements tied to valuation gaps and rate sensitivity. Broader pipeline data point to 40–70 sizable deals potentially completing in the fourth quarter, with catalysts including earnings releases, regulatory filings, and macro data influencing sentiment. This backdrop reflects sustained capital access for quality issuers rather than a guaranteed surge, as historical patterns show deal flow can shift with Treasury yields or risk appetite.